Study of CS-3150 in Patients With Primary Aldosteronism
NCT02885662 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44
Last updated 2018-12-21
Summary
To examine antihypertensive effect and safety of CS-3150 in patients with primary aldosteronism.
Conditions
- Primary Aldosteronism
Interventions
- DRUG
-
CS-3150
CS-3150 2.5 to 5.0 mg , orally.
Sponsors & Collaborators
-
Daiichi Sankyo Co., Ltd.
lead INDUSTRY
Principal Investigators
-
Global Clinical Leader · Daiichi Sankyo
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-09-30
- Primary Completion
- 2017-07-20
- Completion
- 2017-07-20
Countries
- Japan
Study Locations
More Related Trials
-
The Effect of SAAE on Vascular Endothelial Function in PA Patients
NCT05561361 ·Status: RECRUITING
-
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.
NCT00775840 ·Status: COMPLETED ·Phase: PHASE3
-
Aldosterone in Diabetic Nephropathy
NCT00870402 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of Amiloride and Spironolactone in Healthy Persons
NCT00857909 ·Status: COMPLETED ·Phase: PHASE1
-
Diagnosing Variable Primary Aldosteronism.
NCT05765786 ·Status: RECRUITING
-
Multi-omics Studies of Primary Aldosteronism
NCT07111351 ·Status: RECRUITING
-
Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism
NCT06164379 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables
NCT01195805 ·Status: COMPLETED ·Phase: NA
-
Calcium Channel Blockade in Primary Aldosteronism
NCT04179019 ·Status: COMPLETED ·Phase: PHASE2
-
The Long-term Effect of SAAE and Medical Treatment for Primary Aldosteronism
NCT05262660 ·Status: UNKNOWN
-
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
NCT05925569 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism
NCT05814770 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
The Effect of SAAE on Ventricular Remodeling in PA Patients
NCT05501080 ·Status: RECRUITING ·Phase: NA
-
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
NCT02040441 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Plasma Metabolomics Profiling of Primary Aldosteronism
NCT06500000 ·Status: COMPLETED
-
Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertension
NCT04952051 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin
NCT02811055 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism
NCT07137364 ·Status: RECRUITING
-
Adrenal Artery Ablation for Primary Aldosteronism
NCT03653845 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy and Safety of corticoSTEROids Added to Standard Therapy in Patients With Acute Heart Failure (STERO-AHF)
NCT05809011 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Comparison of Three Confirmatory Tests in the Diagnosis of Primary Aldosteronism
NCT04193137 ·Status: COMPLETED
-
The Role of Mineralocorticoid Receptors in Vascular Function
NCT00759525 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Diagnostic Accuracy of Seated Saline Suppression Test for Primary Aldosteronism
NCT03500120 ·Status: COMPLETED
-
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT01853553 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Statin Use on Aldosterone Secretion
NCT02871687 ·Status: COMPLETED ·Phase: PHASE1